title: Pulmonary disposition of vancomycin in critically ill patients.
abstract: Vancomycin penetration in epithelium lining fluid was studied in ten mechanically ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia 24 hours after the onset of treatment. Vancomycin was given intravenously at a daily dose of 30 mg/kg. Vancomycin levels were detectable in four patients (range, 1-2.77 micrograms/ml). Concordance between high plasma concentrations (> 20 micrograms/ml) and detectable vancomycin levels in epithelium lining fluid was noted. These results suggest that the pulmonary disposition of vancomycin remains low for most patients 24 h after the onset of treatment compared with the minimum inhibitory concentrations for most gram-positive organisms. One therapeutic goal of vancomycin treatment could be to obtain through plasma levels of 20 micrograms/ml. Further studies are required to determine the clinical relevance of these observations.
authors.affiliation: Service Universitaire de Réanimation Médicale et Maladies Infectieuses, Hôpital Chatilliez, Tourcoing, France.
authors.forename: H
authors.initials: H
authors.lastname: Georges
authors.forename: O
authors.initials: O
authors.lastname: Leroy
authors.forename: S
authors.initials: S
authors.lastname: Alfandari
authors.forename: B
authors.initials: B
authors.lastname: Guery
authors.forename: M
authors.initials: M
authors.lastname: Roussel-Delvallez
authors.forename: C
authors.initials: C
authors.lastname: Dhennain
authors.forename: G
authors.initials: G
authors.lastname: Beaucaire
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry*; D001999:Bronchoscopy; D016638:Critical Illness; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D012121:Respiration, Artificial; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014640:Vancomycin / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin